Search clinical trials for: Ustekinumab

Total 204 results

Hospices Civils de Lyon

Completed

Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease (SAFARI)

Crohn Disease

France
University of Rochester

Completed

Pilot Trial of Ustekinumab for Primary Sjögren's Syndrome

Primary Sjögren Syndrome

United States
Alvotech Swiss AG
Iqvia Pty Ltd

Completed

Pharmacokinetics, Safety and Tolerability Study of AVT04 to EU Approved and US Licensed Stelara (Ustekinumab)

Psoriasis

Australia, New Zealand
Peking Union Medical College Hospital

Enrolling by invitation

A Multicentered Prospective Cohort Study of Chinese IBD Patients

Crohn Disease | Ulcerative Colitis

China
Samsung Bioepis Co., Ltd.

Completed

A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to European Union (EU) Sourced Stelara and United States of America (US) Sourced Stelara in Healthy Subjects

Healthy

France
BioFactura Australia Pty Ltd.
Avance Clinical Pty Ltd.

Completed

Bioequivalence Phase I Study of BFI-751 Compared With EU and US-STELARA® in Healthy Adults

Psoriasis

Australia, New Zealand
Dr. Frank Behrens
Janssen-Cilag Ltd.

Completed

Impact of Concomitant MTX on Efficacy, Safety and Adherence of Ustekinumab-treatment in Patients With Active PsA (MUST)

Psoriatic Arthritis

Germany
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants

Healthy

United States
Bristol-Myers Squibb

Completed

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

Active Psoriatic Arthritis

Spain, United States, Hungary, Germany, Poland, United Kingdom, Russian Federation, Italy, Czechia
Janssen-Cilag Ltd.

Completed

Prospective Observational Study on Ustekinumab (Stelara) Assessing Efficacy and Healthcare Resource Utilization in Crohn's Disease (PROSE)

Crohn Disease

Sweden
Ola Blennow, MD, PhD
Karolinska University Hospital; Danderyd Hospital; Centrallasarettet Västerås

Active, not recruiting

Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19) (HALT)

Pneumonia, Viral | Covid-19 | Sars-CoV2

Sweden
Tampere University Hospital

Completed

Combination Therapy With Two Biologicals (Combi)

IBD

Finland
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease (STELABEC)

Behçet Disease

France
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age (CADMUS Jr)

Psoriasis

United States, Germany, Taiwan, Belgium, Korea, Republic of, Canada, Poland, Hungary, Netherlands
Novartis Pharmaceuticals

Completed

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab (ARROW)

Chronic Plaque-type Psoriasis

Germany, United States, Canada
Bio-Thera Solutions

Completed

Comparative Study to Evaluate the Pharmacokinetics of BAT2206 vs Stelara® in Healthy Subjects

Psoriasis

China
Janssen Research & Development, LLC

Withdrawn

A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease (DUET)

Crohn Disease

United States
AbbVie
Boehringer Ingelheim

Completed

BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Celltrion

Completed

Study to Compare PK and Safety of Subcutaneous Injection of Ustekinumab and CT-P43 in Healthy Subjects

Healthy Subjects

New Zealand
AbbVie
Boehringer Ingelheim

Completed

BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis
Second Affiliated Hospital, School of Medicine,...

Unknown

The Safety and Effectiveness of Local Injection of Antihistamines in Treatment of Inflammatory Skin Diseases

Inflammatory Skin Disease

China
Janssen Pharmaceutica N.V., Belgium

Completed

A Study on Assessment of STELARA and Tumor Necrosis Factor Alpha Inhibitor Therapies in Participants With Psoriatic Arthritis (PsaBio)

Psoriatic Arthritis

France, United Kingdom, Belgium, Spain, Netherlands, Greece, Russian Federation
National Eye Institute (NEI)

Completed

Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)

Uveitis

United States
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Pfizer

Completed

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

Urinary Bladder, Neurogenic

Japan
Janssen Research & Development, LLC

No longer available

An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease

Crohn Disease

Brazil
Janssen Research & Development, LLC

Withdrawn

A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

China
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)

Crohn's Disease | Colitis | Inflammatory Bowel Disease | IBD

United States, France, Poland, United Kingdom, Germany, Spain, Israel, Bulgaria, Serbia, South Africa, Japan, Canada, Australia, Netherlands, Korea, Republic of, Belgium, New Zealand, Brazil, Russian Federation, Austria, Hungary, ... and more
Janssen Research & Development, LLC

Completed

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

Psoriatic Arthritis

United States, Germany, Spain, Poland, Romania, Canada, Russian Federation
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.

Terminated

Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation (deLTa)

Liver Transplantation

United States
National Institute of Allergy and Infectious Diseases...

Completed

Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

CVID Enteropathy | Gastrointestinal Inflammation Associated With CVID

United States
Eli Lilly and Company

Completed

A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis (IXORA-S)

Plaque Psoriasis

Germany, Spain, Belgium, France, Hungary, Austria, Canada, Italy, Netherlands, Poland, Sweden, Switzerland, United Kingdom
Massachusetts General Hospital

Terminated

Ustekinumab for the Treatment of Giant Cell Arteritis (UGCA)

Giant Cell Arteritis | Horton's Disease | Temporal Arteritis

United States
Janssen Cilag S.A.S.

Completed

A Study to Characterize Profile of Participant With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab (PROUST)

Psoriatic Arthritis

France
Janssen Research & Development, LLC

Completed

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Poland, Germany, Spain, Mexico, Australia, Taiwan, Argentina, Hungary
H. Lee Moffitt Cancer Center and Research Institute
Gateway for Cancer Research

Completed

Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease (Ustekinumab)

Graft vs. Host Disease

United States
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Bausch Health Americas, Inc.

Terminated

Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-3)

Plaque Psoriasis

United States, Belgium, Italy, Hungary, Poland, Australia, France, Greece, Russian Federation, Latvia, Canada
National Eye Institute (NEI)

Withdrawn

Ustekinumab for Active Sight-Threatening Uveitis

Uveitis
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Ukraine, Taiwan, Poland, Korea, Republic of, Russian Federation, Czechia
Janssen Research & Development, LLC

Terminated

A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis

Axial Spondyloarthritis

United States, Canada, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Argentina, Mexico, Poland, Portugal, Bulgaria, Korea, Republic of, Brazil, Russian Federation, Hungary, Czechia
University of Pennsylvania
Janssen Scientific Affairs, LLC

Completed

Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U) (VIP-U)

Cardiovascular Disease | Psoriasis

United States
Novartis Pharmaceuticals

Completed

Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis (CLARITY)

Plaque Psoriasis

United States, Hungary, Malaysia, Czechia, Korea, Republic of, Guatemala, Poland, Vietnam, Canada, Iceland, Slovakia
Janssen Research & Development, LLC

Terminated

An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

Nonradiographic Axial Spondylitis, Ankylosing

Australia, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Argentina, Mexico, Poland, Korea, Republic of, Russian Federation, Hungary, Czechia
Fundación de Investigación Biomédica - Hospital...

Completed

Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells

Inflammatory Bowel Disease
Janssen Biotech, Inc.

Completed

Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database

Psoriasis
Yonsei University

Unknown

A Phase II Trial of Afatinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of Esophagus

Squamous Cell Carcinoma of Esophagus

Korea, Republic of
National Institute of Allergy and Infectious Diseases...
Immune Tolerance Network (ITN)

Completed

Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris (PAUSE)

Psoriasis

United States, Canada
Saint Thomas Health
Pfizer

Withdrawn

Neuropathic Investigation and Anticholinergic Treatment of Bladder Dysfunction in Diabetes and Stroke Patients

Urinary Incontinence | Bladder Dysfunction

United States
Universitaire Ziekenhuizen KU Leuven

Unknown

Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions (STRAUSS)

Inflammatory Bowel Diseases | Psoriasis

Search clinical trials for: Ustekinumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations